PTP1B Inhibitory and Anti-Inflammatory Effects of Secondary Metabolites Isolated from the Marine-Derived Fungus Penicillium sp. JF-55

Dong‐Sung Lee, Jae‐Hyuk Jang, Wonmin Ko, Kyoung-Su Kim, Jae Ho Sohn, Myeong-Suk Kang, Jong Chul Ahn, Youn‐Chul Kim, Hyuncheol OhMarine 2013 · DOI

TL;DR

This study identifies a novel compound, penstyrylpyrone, from a marine fungus that inhibits Protein Tyrosine Phosphatase 1B (PTP1B), a key target for diabetes treatment. Penstyrylpyrone also exhibits significant anti-inflammatory effects by modulating the NF-κB pathway and inducing heme oxygenase-1 (HO-1).

What Problem Does This Paper Address?

Diabetes, particularly Type 2, is a growing global health concern often linked to insulin resistance. Protein Tyrosine Phosphatase 1B (PTP1B) is a critical enzyme that negatively regulates insulin signaling, making it a prime therapeutic target for improving insulin sensitivity. Simultaneously, inflammation is increasingly recognized as a contributing factor to metabolic diseases like diabetes. The transcription factor NF-κB is a central regulator of inflammatory responses, and its dysregulation is implicated in various inflammatory conditions. This paper addresses the need for novel therapeutic agents that can simultaneously target both insulin resistance (via PTP1B inhibition) and inflammation (via NF-κB modulation), potentially offering a dual-action approach to managing metabolic and inflammatory diseases.

Methods

The researchers employed a bioassay-guided isolation strategy to identify bioactive compounds from a marine-derived fungus, Penicillium sp. JF-55. This involved:

  • Extraction and Chromatography: Methylethylketone extract of the fungal culture was subjected to various chromatographic techniques (C18 flash column chromatography, semi-preparative reversed-phase HPLC) to isolate pure compounds.
  • Structure Elucidation: Spectroscopic methods, including 1D and 2D NMR (¹H, ¹³C, DEPT, HSQC, HMBC) and HRESIMS, were used to determine the chemical structures of the isolated compounds.
  • PTP1B Inhibition Assay: An in vitro assay was used to measure the inhibitory activity of the compounds against PTP1B. Kinetic analyses (Lineweaver-Burk plots) were performed to determine the mechanism of inhibition.
  • Anti-inflammatory Assays:
    • Nitrite and PGE2 Production: Murine peritoneal macrophages were stimulated with lipopolysaccharide (LPS) and treated with compounds. Nitrite (a marker for NO production) and PGE2 levels were measured using the Griess reaction and ELISA kits, respectively.
  • Protein Expression: Western blotting was used to assess the expression levels of key inflammatory proteins like iNOS and COX-2.
  • Cytokine Production: ELISA kits were used to quantify the production of pro-inflammatory cytokines TNF-α and IL-1β.
  • NF-κB Pathway Analysis: Western blotting was used to examine the phosphorylation and degradation of IκB-α, NF-κB (p65) translocation into the nucleus, and NF-κB DNA-binding activity using an ELISA kit.
  • HO-1 Expression and Nrf2 Translocation: Western blotting was used to evaluate HO-1 protein expression and Nrf2 nuclear translocation. ARE (antioxidant response element) activation was assessed using a luciferase reporter assay.
  • Inhibitor Studies: The effect of tin protoporphyrin IX (SnPP), an HO-1 inhibitor, was investigated to confirm the role of HO-1 in the observed anti-inflammatory effects.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Novel Marine Natural Product: The isolation of a new styrylpyrone-type metabolite, penstyrylpyrone (1), from a marine fungus highlights the untapped potential of marine microorganisms as sources of novel bioactive compounds.
  • Dual Therapeutic Potential: Penstyrylpyrone demonstrates a promising dual mechanism of action: inhibiting PTP1B (relevant for diabetes) and suppressing inflammatory pathways (relevant for metabolic and inflammatory diseases).
  • Competitive PTP1B Inhibition: The kinetic analysis revealing a competitive inhibition mechanism for penstyrylpyrone and anhydrofulvic acid suggests they bind to the active site of PTP1B, offering a specific mode of action.
  • NF-κB as a Central Target: Penstyrylpyrone's ability to suppress multiple pro-inflammatory mediators (NO, PGE2, TNF-α, IL-1β) by inhibiting NF-κB activation (through reduced IκB-α degradation and NF-κB translocation) underscores its potent anti-inflammatory capabilities.
  • HO-1 Induction as a Mediator: The study strongly suggests that penstyrylpyrone's anti-inflammatory effects are mediated, at least in part, by the induction of heme oxygenase-1 (HO-1) via the Nrf2 pathway. This is a significant finding as HO-1 is known for its anti-inflammatory properties.
  • Synergistic Action: The interplay between NF-κB inhibition and HO-1 induction by penstyrylpyrone suggests a complex but effective anti-inflammatory cascade.

Key Results

  • Compound Isolation: A new compound, penstyrylpyrone (1), and two known compounds, anhydrofulvic acid (2) and citromycetin (3), were isolated from Penicillium sp. JF-55.
  • PTP1B Inhibition:
    • Penstyrylpyrone (1) showed an IC50 of 5.28 µM.
  • Anhydrofulvic acid (2) showed an IC50 of 1.90 µM.
  • Citromycetin (3) showed no significant inhibitory activity up to 25.8 µM.
  • Inhibition was determined to be competitive.
  • Anti-inflammatory Effects of Penstyrylpyrone (1):
    • Inhibited NO production with an IC50 of 12.32 µM.
  • Inhibited PGE2 production with an IC50 of 9.35 µM.
  • Reduced iNOS and COX-2 protein expression.
  • Reduced TNF-α and IL-1β production.
  • Inhibited LPS-induced NF-κB DNA-binding activity.
  • Induced HO-1 expression in a concentration- and time-dependent manner.
  • Promoted Nrf2 nuclear translocation and ARE activation.
  • The anti-inflammatory effects were partially reversed by the HO-1 inhibitor SnPP.

Limitations and Future Work

  • In Vivo Studies: The study was primarily conducted using in vitro assays and cell-based models. Further in vivo studies are needed to confirm the efficacy and safety of penstyrylpyrone in animal models of diabetes and inflammation.
  • Mechanism Elucidation: While the study provides strong evidence for the involvement of PTP1B, NF-κB, and HO-1, a more detailed mechanistic understanding of how penstyrylpyrone interacts with these pathways could be explored.
  • Structure-Activity Relationship: Further investigation into the structure-activity relationship of penstyrylpyrone and related styrylpyrones could lead to the development of more potent analogs.
  • Toxicity Assessment: Comprehensive toxicity studies are necessary before considering clinical applications.

The authors suggest that penstyrylpyrone's ability to modulate multiple targets (PTP1B, NF-κB, HO-1) makes it a promising therapeutic candidate for type II diabetes and inflammatory diseases.

Summary updated

Abstract

Protein tyrosine phosphatase 1B (PTP1B) plays a major role in the negative regulation of insulin signaling, and is thus considered as an attractive therapeutic target for the treatment of diabetes. Bioassay-guided investigation of the methylethylketone extract of marine-derived fungus Penicillium sp. JF-55 cultures afforded a new PTP1B inhibitory styrylpyrone-type metabolite named penstyrylpyrone (1), and two known metabolites, anhydrofulvic acid (2) and citromycetin (3). Compounds 1 and 2 inhibited PTP1B activity in a dose-dependent manner, and kinetic analyses of PTP1B inhibition suggested that these compounds inhibited PTP1B activity in a competitive manner. In an effort to gain more biological potential of the isolated compounds, the anti-inflammatory effects of compounds 1-3 were also evaluated. Among the tested compounds, only compound 1 inhibited the production of NO and PGE2, due to the inhibition of the expression of iNOS and COX-2. Penstyrylpyrone (1) also reduced TNF-α and IL-1β production, and these anti-inflammatory effects were shown to be correlated with the suppression of the phosphorylation and degradation of IκB-α, NF-κB nuclear translocation, and NF-κB DNA binding activity. In addition, using inhibitor tin protoporphyrin (SnPP), an inhibitor of HO-1, it was verified that the inhibitory effects of penstyrylpyrone (1) on the pro-inflammatory mediators and NF-κB DNA binding activity were associated with the HO-1 expression. Therefore, these results suggest that penstyrylpyrone (1) suppresses PTP1B activity, as well as the production of pro-inflammatory mediators via NF-κB pathway, through expression of anti-inflammatory HO-1.
BibTeX
@inproceedings{lee2013ptp,
  author = {Dong‐Sung Lee and Jae‐Hyuk Jang and Wonmin Ko and Kyoung-Su Kim and Jae Ho Sohn and Myeong-Suk Kang and Jong Chul Ahn and Youn‐Chul Kim and Hyuncheol Oh},
  title = {{PTP1B Inhibitory and Anti-Inflammatory Effects of Secondary Metabolites Isolated from the Marine-Derived Fungus Penicillium sp. JF-55}},
  booktitle = {Marine},
  year = {2013},
  doi = {10.3390/md11041409},
}
Figure